Climb Bio (CLYM) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Climb Bio (CLYM) has outperformed Silence Therapeutics Plc American Depository Share (SLN) over the past year, gaining 503.3% versus a gain of 81.3%. Over five years, CLYM leads with a -32.7% price change compared with -56.4% for SLN. Climb Bio is the larger company by market cap ($623.8 million vs $591.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLYM | SLN |
|---|---|---|
| Share price | $10.86 | $9.52 |
| Market cap | $623.76M | $591.71M |
| 1-day change | +1.40% | -3.05% |
| YTD return | +171.50% | +56.58% |
| 1-year return | +503.33% | +81.33% |
| 5-year return | -32.71% | -56.37% |
| EPS (TTM) | $-0.82 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.33 | $17.58 |
| 52-week low | $1.64 | $4.19 |
| Distance from 52-week high | -40.75% | -45.84% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +153.87% | +246.64% |
| Average volume | 1.37M | 1.14M |
| Shares outstanding | 57.44M | 62.15M |
| Employees | 28 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed SLN by 422.0 percentage points over the past year.
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
CLYM vs SLN FAQ
Which is bigger, Climb Bio or Silence Therapeutics Plc American Depository Share?
Climb Bio (CLYM) is larger, with a market capitalization of $623.76M compared with $591.71M for Silence Therapeutics Plc American Depository Share (SLN).
Which stock has performed better over the past year, CLYM or SLN?
CLYM returned +503.33% over the past 12 months, compared with +81.33% for SLN (price return, excluding dividends). Past performance does not predict future results.
Are Climb Bio and Silence Therapeutics Plc American Depository Share in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.